Drug Database
DE

desloratadine + pseudoephedrine (Clarinex D / Aerinaze)

✓ Approved

Merck & Co. · HRH1 · Small Molecule

What is desloratadine + pseudoephedrine?

desloratadine + pseudoephedrine is a small molecule developed by Merck & Co.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesClarinex D, Aerinaze
CompanyMerck & Co.
Drug ClassSmall Molecule
Molecular TargetHRH1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Merck & Co.

Mechanism of Action

Molecular Targets

desloratadine + pseudoephedrine acts on 1 molecular target:

HRH1histamine receptor H1 (HH1R, H1R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

desloratadine + pseudoephedrine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersSeasonal allergy✓ Approved

Related Research Articles

PubMedChemistry (Weinheim an der Bergstrasse, Germany)2026-11-05

Total Synthesis and Absolute Configuration of the Irregular Tetraterpene Viaticene A.

Stamm Patrick P, Solak Ozan O, Kuhn Johanna J, Schulz Stefan S

Viaticenes are tetraterpenes with a unique [6+2]-connectivity known from the epicuticular lipid layer of the springtail Hypogastrura viatica. Here, we report the total synthesis of viaticene A in thirteen steps from methyl 5-hexynoate, with an overall yield of 16%. Key steps in the construction of the core fragment include the stereoselective introduction of the E- and Z-double bonds via silyl- and carbocupration, respectively, and establishment of the central stereogenic center using pseudoephedrine as a chiral auxiliary. Subsequently, C9- and C11-alkyl building blocks are coupled to the core fragment via copper-mediated allylic substitution and nickel/cobalt-cocatalyzed vinyl-alkyl cross-electrophile coupling, preventing double-bond migration in the latter reaction with the novel additive combination styrene/water/molecular sieves. The modular synthesis route gives selective access to relevant diastereomers, allowing determination of the absolute configuration of viaticene A. Configurations at C-3, C-7, and C-19 are elucidated through careful analysis of the 13C-NMR spectra, assigning the all-R-configuration to the natural product.

PMID 42983587
Read full article →
PubMedJournal of visualized experiments : JoVE2026-10-31

Combination Therapy of Montelukast and Desloratadine in Pediatric Allergic Rhinitis: Effects on Symptoms and Inflammatory Markers.

Wang Jingfeng J, Huang Dongdong D, Cai Zhang Z, Lin Qiming Q

This retrospective, controlled study evaluated the clinical outcomes of montelukast sodium combined with desloratadine syrup in pediatric patients with allergic rhinitis. Medical records from 360 children aged 6-12 years treated between October 2021 and November 2024 were reviewed. Patients were classified according to documented treatment as desloratadine monotherapy (Group A, n = 180) or desloratadine plus montelukast (Group B, n = 180). During the 4-week treatment period, Total Nasal Symptom Score (TNSS), Total Non-Nasal Symptom Score (TNNSS), time to symptom improvement, serum immunoglobulin E (IgE), interleukin-13 (IL-13), eosinophil counts, and adverse events were assessed. Group B had lower post-treatment TNSS (4.65 ± 2.12 vs 5.32 ± 2.09, p = 0.003) and TNNSS (1.96 ± 1.43 vs 2.48 ± 1.01, p < 0.001), and rhinorrhea improved sooner (10.38 ± 1.87 vs 13.48 ± 1.20 days, p < 0.001). Greater reductions were also observed in inflammatory markers, including IgE and IL-13 (90.36 ± 22.58 vs 102.78 ± 19.25 ng/L, p < 0.001). Adverse-event rates did not differ significantly (0.56% vs 1.67%; Fisher's exact test, p = 0.623), although only four events were recorded. These findings indicate that combination therapy was associated with greater improvements in clinical symptoms and inflammatory markers than desloratadine monotherapy; however, the retrospective, nonrandomized design and limited safety events require cautious interpretation.

PMID 42965351
Read full article →
PubMedBMC chemistry2026-10-22

Eco-sustainable organic solvent-free spectrophotometric method for the concurrent determination of a ternary pharmaceutical mixture.

Hamdy Abdallah M AM, Meselhy Esraa M EM, El Henawee Magda M MM, Hashem Hisham H et al.

In recent years, green analytical chemistry has become essential in pharmaceutical research, aiming to mitigate environmental hazards associated with conventional analytical practices. The current focus lies in optimizing analytical methods to achieve both environmental and economic sustainability. In this framework, three environmentally sustainable spectrophotometric methods were developed for simultaneous analysis of three co-formulated drugs: acetaminophen, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride, which are often used to alleviate symptoms associated with COVID-19. The employed spectrophotometric methodologies include the double divisor-ratio spectra derivative method, the mean centering of double divisor ratio spectra method, and the dual wavelength in ratio spectrum method. The innovative techniques displayed good linearity within 25-350 µg/mL for dextromethorphan hydrobromide, 2-24 µg/mL for acetaminophen, and 100-1400 µg/mL for pseudoephedrine hydrochloride. The environmental sustainability of the proposed methods was evaluated using the Analytical Eco-Scale, analytical greenness metric, and the Green Analytical Procedure Index. Furthermore, complementary evaluations of blueness and whiteness were conducted through the Blue Applicability Grade Index and the Red Green Blue 12 metric, respectively. The collective outcomes of all evaluation metrics clearly demonstrated that the proposed methods possess enhanced environmental compatibility and sustainability relative to the existing techniques. The proposed methods were fully validated according to the International Conference on Harmonization recommendations. The developed methods offered a cost-effective and eco-friendly approach for concurrent determination of acetaminophen, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride in their bulk substances, and pharmaceutical formulations.

PMID 42907898
Read full article →
PubMedSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026-10-19

Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study.

Makihara Katsuya K, Kongo Keisuke K, Motomura Kayo K, Kimoto Daiki D et al.

Docetaxel (DTX) causes skin toxicities despite dexamethasone-based supportive care, and no established adjunctive primary prophylaxis exists. We assessed whether desloratadine, a peripheral H1-receptor antagonist with anti-inflammatory properties, was associated with DTX-related skin toxicities in early-stage breast cancer. This single-center retrospective cohort included 143 patients with stage I-III breast cancer receiving perioperative DTX-based chemotherapy (75 mg/m2 every 3 weeks) with dexamethasone premedication. Desloratadine (5 mg daily from the morning after first DTX infusion through treatment completion) was prescribed nonrandomly to 49 patients (34.3%); 94 received no prophylactic antihistamine. The primary outcome was any patient-reported skin toxicity (rash, pruritus, or hand-foot syndrome [HFS]). The primary analysis used Hájek-normalized stabilized inverse probability of treatment weighting (IPTW), with 95% confidence intervals (CIs) from 2,000 patient-level bootstrap resamples with propensity-score refitting. Calendar-time confounding was assessed by post-implementation restriction. After stabilized IPTW, skin-toxicity incidence was 46.2% with desloratadine and 70.7% without it (risk difference, - 24.6 percentage points; 95% CI, - 43.0 to - 5.3; risk ratio [RR], 0.65; 95% CI, 0.42-0.92). Descriptive estimates indicated lower pruritus incidence (RR, 0.36; 95% CI, 0.08-0.79), a lower but imprecise rash estimate (RR, 0.70; 95% CI, 0.43-1.03), and no lower HFS incidence (5.9% vs 5.4%). Post-implementation findings were similar (RR, 0.61; 95% CI, 0.42-0.90); negative-control neuropathy was not lower (RR, 1.19; 95% CI, 0.52-2.58). Desloratadine prophylaxis was associated with lower skin-toxicity risk, particularly for pruritus. Rash risk was lower but imprecisely estimated; HFS risk was not lower. These hypothesis-generating findings warrant validation in a prospective randomized trial.

PMID 42895563
Read full article →
PubMedThe Journal of allergy and clinical immunology2026-10-16

Comparative efficacy and safety of antihistamines, increased antihistamine dosing, and antihistamine adjuncts for chronic urticaria: a systematic review, dose-response, and network meta-analysis of randomized trials.

Chu Alexandro W L AWL, Zhao Irene X IX, Rayner Daniel G DG, Guyatt Gordon H GH et al.

Chronic urticaria is a common immune-mediated condition characterized by wheals (itch and hives), angioedema, or both, lasting for greater than six weeks. It is managed with H1 antihistamines as the first-line therapy. Fundamental unresolved questions remain regarding the comparative benefits and harms of antihistamines and their adjuncts, and of H1 antihistamine dose-escalation. To analyze the comparative benefits and harms of antihistamines and their adjuncts (H2 blockers or montelukast), and of H1 antihistamine dose-escalation. As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random effects network and dose-response meta-analyses addressed urticaria activity (composed of itch and wheal scores), angioedema activity, urticaria-related quality of life, and harms including sedation. The GRADE approach informed certainty of evidence ratings. CRD42022367280. 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, fexofenadine, and levocetirizine are among the most effective in improving overall urticaria activity, urticaria-related quality of life, and sleep disturbance. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also among the most effective in improving urticaria-related quality of life. Escalating from a single to quadruple daily dose may yield diminishing additional benefit. Second-generation agents as a class may be more effective than first-generation agents in improving urticaria activity and sleep disturbance. Sedation risk likely increases with higher doses, with first-generation agents (e.g., diphenhydramine, hydroxyzine) and doxepin among the most sedating; cetirizine, ketotifen, levocetirizine, and rupatadine among the intermediate sedating; and bepotastine, bilastine, desloratadine, ebastine, fexofenadine, and loratadine among the least sedating. Adding montelukast (moderate certainty) or an H2 blocker (very low certainty) to a second-generation agent may further reduce urticaria activity. For chronic urticaria, second-generation agents differ in their efficacy and safety. First-generation agents are less beneficial and more harmful. Escalating to higher daily doses may provide additional benefits but likely increases sedation.

PMID 42887704
Read full article →
PubMedThe American Journal of dermatopathology2026-10-15

Neutrophilic Fixed Drug Eruption Mimicking Neutrophilic Dermatosis: Two Cases, Including Sequential Biopsies Demonstrating Time-Dependent Histopathology.

Chamninawakul Padol P, Lim Ziying Vanessa ZV, Khoo Lawrence Shih Wee LSW, Lee Joyce Siong See JSS

Fixed drug eruption (FDE) is classically a lymphocyte-predominant interface dermatitis, but an early lesion may show a prominent neutrophilic infiltrate that closely simulates a primary neutrophilic dermatosis. We report 2 cases. The first, a 42-year-old woman, developed a multifocal eruption approximately 45 minutes after re-exposure to etoricoxib, recurring at previously affected and new sites. A punch biopsy performed 21 hours after ingestion of the drug showed a basketweave stratum corneum, intense papillary dermal edema with pseudovesiculation, and a superficial and deep infiltrate rich in neutrophils with karyorrhexis, closely resembling Sweet syndrome. Only occasional apoptotic keratinocytes were present within the epidermis, and the marked edema obscured any interface dermatitis, although admixed eosinophils were noted. Clinicopathologic correlation ultimately established the diagnosis of neutrophilic FDE. The second, a 55-year-old man, had an eruption recurring at the same sites after pseudoephedrine. A biopsy of an established lesion 2-3 weeks after ingestion showed classic interface dermatitis with numerous eosinophils and pigment incontinence, whereas one taken from the same region within 24 hours of re-exposure showed a neutrophil-predominant infiltrate with prominent karyorrhexis and only focal interface change. These cases, biopsied at documented time points, support the concept that the neutrophil-rich appearance of FDE represents an early phase in its histopathologic evolution, demonstrate how it can be mistaken for a neutrophilic dermatosis in the absence of adequate clinical history, and show that clinicopathologic correlation and a high index of suspicion are necessary to reliably arrive at the correct diagnosis.

PMID 42878618
Read full article →

+2316 more articles available with a free account

Sign up free to view all articles →

Ask about desloratadine + pseudoephedrine